Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11840965 | 0.98 | CYP2D6 (0.44) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL11846170 | 0.95 | MEN1 (0.46) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL19158572 | 0.89 | MEN1 (0.49) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL4540545 | 0.85 | HTR2C (0.54) | CYP2D6HTR2ABCHEHTR2CHTR2B | |
| SCHEMBL1248364 | 0.85 | BCHE (0.41) | CYP2D6MEN1CYP3A4KMT2ABCHE | |
| SCHEMBL17120414 | 0.82 | MEN1 (0.51) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL17121746 | 0.82 | MEN1 (0.51) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL26201345 | 0.82 | MEN1 (0.51) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL29700481 | 0.79 | MEN1 (0.49) | CYP2D6MEN1CYP3A4KMT2AHTR2A | |
| SCHEMBL20227872 | 0.77 | CYP2D6 (0.41) | CYP2D6MEN1CYP3A4KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761083-B | 5-HT for treating depression 2A Agonists | 罗福拉公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-114761083-A | 5-HT for the treatment of depression2AAgonists | 罗福拉公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
| CN-101258130-B | Isoquinolines as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA | 2012-11-28 | — | — | CN | disclosed |
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
| CN-101258130-A | Isoquinolines as insulin-like growth factor-1 receptor inhibitors | ANALYTECON SA (CH) | 2008-09-03 | — | — | CN | disclosed |
| EP-1931636-A1 | ISOQUINOLINES AS IGF-1R INHIBITORS | Analytecon S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029106-A1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | CYP2D6 498/4885MEN1 4160/4885CYP3A4 1541/4885 |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | CYP2D6 3702/4885MEN1 893/4885CYP3A4 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.